Boston Scientific price target lowered to $99 from $112 at Goldman Sachs

Goldman Sachs lowered the firm’s price target on Boston Scientific (BSX) to $99 from $112 and keeps a Buy rating on the shares. Boston Scientific posted mixed Q4 results, with in-line revenue and a tax rate-driven EPS beat, this is the first quarter over the past two years when the company has not posted more meaningful top- and bottom-line upside vs. consensus, the analyst tells investors in a research note. The firm sees greater onus on upcoming clinical trial readouts as well as greater scrutiny on growth driver components throughout the year.